Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 2,546 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,546 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $30.68, for a total transaction of $78,111.28. Following the completion of the sale, the insider directly owned 21,479 shares of the company’s stock, valued at approximately $658,975.72. The trade was a 10.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

NASDAQ CSTL traded up $0.07 during trading on Thursday, reaching $30.47. The company’s stock had a trading volume of 833,433 shares, compared to its average volume of 407,908. The firm has a 50 day moving average price of $23.38 and a 200 day moving average price of $26.23. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The firm has a market capitalization of $930.86 million, a price-to-earnings ratio of -46.17 and a beta of 0.98. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The company had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. As a group, equities analysts anticipate that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Roth Capital began coverage on Castle Biosciences in a research note on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target for the company. KeyCorp set a $35.00 price objective on shares of Castle Biosciences in a research report on Friday, May 29th. Finally, Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Key Castle Biosciences News

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth prospects and implies meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle’s latest quarterly performance exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the loss of $0.07 per share was narrower than the expected $0.41 loss. The results support the view that operating performance is improving, although the company remains unprofitable.
• Positive Sentiment: Wall Street sentiment remains generally favorable, with an overall “Moderate Buy” consensus rating and an average price target of approximately $42. Institutional investors and hedge funds own about 92.6% of outstanding shares, while several funds recently increased their positions.
• Negative Sentiment: Several Castle Biosciences insiders sold shares. Derek J. Maetzold sold more than 39,000 shares across August 4–5, COO Kristen Oelschlager sold 8,586 shares, and Tobin W. Juvenal also reported a sale. The transactions reduced the executives’ holdings and could weigh on sentiment, particularly following the stock’s recent strength. However, the sales were conducted under pre-arranged Rule 10b5-1 plans, making them a less decisive bearish signal than discretionary selling. Castle Biosciences insider sales filing

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. Truist Financial Corp grew its position in Castle Biosciences by 1.1% during the 4th quarter. Truist Financial Corp now owns 23,628 shares of the company’s stock worth $919,000 after acquiring an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the last quarter. CWM LLC boosted its stake in shares of Castle Biosciences by 20.5% during the fourth quarter. CWM LLC now owns 2,302 shares of the company’s stock valued at $90,000 after purchasing an additional 391 shares in the last quarter. HRT Financial LP boosted its stake in shares of Castle Biosciences by 0.9% during the fourth quarter. HRT Financial LP now owns 47,654 shares of the company’s stock valued at $1,853,000 after purchasing an additional 415 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in shares of Castle Biosciences by 9.3% during the first quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock valued at $142,000 after purchasing an additional 492 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.